The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Definity
perflutren · PERFLUTREN 6.52 mg/mL · Injection, Suspension · Intravenous · Lantheus Medical Imaging, Inc.
NDC 11994-0011-04 · 4 VIAL, GLASS in 1 CARTON / 1.5 mL in 1 VIAL, GLASS · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$1,483.01
Reported to Texas DSHS · 2025 annual filing · Lantheus Medical Imaging, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 1 ML
$40.854
HCPCS Q9957 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$1.2M
13,519 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Jubilant HollisterStier LLCUnited Statesmanufacture
- Lantheus Medical Imaging, Inc.United Statesanalysis · label · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA021064
- TE code
- —
- Approval date
- Jul 31, 2001
- Patents / exclusivity
- 20 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 10588988 | May 4, 2037 |
| patent | 10588988 | May 4, 2037 |
| patent | 9789210 | Mar 16, 2037 |
| patent | 9789210 | Mar 16, 2037 |
| patent | 10583208 | Mar 16, 2037 |
| patent | 11266750 | Mar 16, 2037 |
| patent | 11266750 | Mar 16, 2037 |
| patent | 12161730 | Mar 16, 2037 |
| patent | 12161730 | Mar 16, 2037 |
| patent | 10583208 | Mar 16, 2037 |
| patent | 11925695 | Mar 16, 2037 |
| patent | 11925695 | Mar 16, 2037 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of perflutren (Injection, Suspension)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Lantheus Medical Imaging, Inc. | PERFLUTREN 6.52 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Jubilant HollisterStier LLC | PERFLUTREN 6.52 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Samsung Biologics Co., Ltd. | PERFLUTREN 6.52 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Definity — NDC 11994-0011-04," retrieved September 3, 2026, https://drugdashboards.com/drug/11994001104.
Free to cite with attribution — see how the data is put together.